Literature DB >> 29968562

In Reply.

Thorsten Derlin.   

Abstract

Year:  2018        PMID: 29968562      PMCID: PMC6050435          DOI: 10.3238/arztebl.2018.0417b

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN: 1866-0452            Impact factor:   5.594


× No keyword cloud information.
  4 in total

1.  Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation.

Authors:  Shira L Galper; James B Yu; Peter M Mauch; Jon F Strasser; Barbara Silver; Ann Lacasce; Karen J Marcus; Mary Ann Stevenson; Ming Hui Chen; Andrea K Ng
Journal:  Blood       Date:  2010-09-21       Impact factor: 22.113

2.  Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial.

Authors:  Andreas Engert; Heinz Haverkamp; Carsten Kobe; Jana Markova; Christoph Renner; Antony Ho; Josée Zijlstra; Zdenek Král; Michael Fuchs; Michael Hallek; Lothar Kanz; Hartmut Döhner; Bernd Dörken; Nicole Engel; Max Topp; Susanne Klutmann; Holger Amthauer; Andreas Bockisch; Regine Kluge; Clemens Kratochwil; Otmar Schober; Richard Greil; Reinhard Andreesen; Michael Kneba; Michael Pfreundschuh; Harald Stein; Hans Theodor Eich; Rolf-Peter Müller; Markus Dietlein; Peter Borchmann; Volker Diehl
Journal:  Lancet       Date:  2012-04-04       Impact factor: 79.321

Review 3.  Molecular Imaging in Oncology Using Positron Emission Tomography.

Authors:  Thorsten Derlin; Viktor Grünwald; Jörg Steinbach; Hans-Jürgen Wester; Tobias L Ross
Journal:  Dtsch Arztebl Int       Date:  2018-03-16       Impact factor: 5.594

4.  Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma.

Authors:  John Radford; Tim Illidge; Nicholas Counsell; Barry Hancock; Ruth Pettengell; Peter Johnson; Jennie Wimperis; Dominic Culligan; Bilyana Popova; Paul Smith; Andrew McMillan; Alison Brownell; Anton Kruger; Andrew Lister; Peter Hoskin; Michael O'Doherty; Sally Barrington
Journal:  N Engl J Med       Date:  2015-04-23       Impact factor: 91.245

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.